IDH1 and OCT4 in high-grade astrocytoma
Part of Cancer clinical trials.
This trial looks at two markers, IDH1 and OCT4, in high-grade astrocytoma (a type of brain tumor). It may help doctors better understand the tumor and guide treatment. Patients with high-grade astrocytoma who can have surgery may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with high-grade astrocytoma (a more aggressive brain tumor).
- You are able to have surgery to remove the tumor.
- You do not have a low-grade glioma (a less aggressive brain tumor).
- Your doctor has said you are fit for surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two oral medications, olutasidenib and temozolomide, for people with a specific type of aggressive brain tumor (high-grade glioma) that has an IDH1 mutation. The goal is to see if this combination can help control the tumor after standard treatment like radiation.
This study analyzes tissue and health-related biological data from people with glioblastoma to learn what’s happening in the tumor. The results may help improve future ways to understand and treat glioblastoma using advanced computer analysis.
This Phase 2 study tests a combination of chemotherapy and radiation after surgery for certain brain tumors that are “IDH wildtype.” It aims to control the tumor and improve outcomes for people with specific types of glioma or glioblastoma.
This trial uses a special PET scan to see how IDH-mutant gliomas respond to treatment. It may help your doctor better track your tumor's activity.
This early-stage study tests ASTX727 in adults with IDH-mutant gliomas that are coming back or progressing. It aims to see whether the medicine can slow the tumor and understand how it works in the body and tumor tissue.
This trial tests a combination of two drugs (D2C7-IT and 2141-V11) given directly into the brain after surgery for people with recurrent glioblastoma. The goal is to see if this treatment is safe and can help control the tumor.
Hear when a new High Grade Astrocytoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.